Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia

Leukemia. 2014 Jul;28(7):1545-8. doi: 10.1038/leu.2014.58. Epub 2014 Feb 5.

Authors

K Matsuda¹, Y Nakazawa², C Iwashita¹, T Kurata², K Hirabayashi², S Saito², M Tanaka², K Yoshikawa², R Yanagisawa², K Sakashita², S Sasaki³, T Honda¹, K Koike²

Affiliations

¹ Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
² Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
³ Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan.

PMID: 24496301
DOI: 10.1038/leu.2014.58

No abstract available

Publication types

Letter

MeSH terms

Child, Preschool
Drug Resistance, Neoplasm / genetics
Female
Humans
Infant
Leukemia, Myelomonocytic, Juvenile / drug therapy*
Leukemia, Myelomonocytic, Juvenile / genetics*
Leukemia, Myelomonocytic, Juvenile / metabolism
Male
Mercaptopurine / pharmacology*
Mercaptopurine / therapeutic use*
Mutation*
Neoplastic Stem Cells / drug effects*
Neoplastic Stem Cells / metabolism*
Protein Tyrosine Phosphatase, Non-Receptor Type 11 / genetics*
Signal Transduction
Treatment Outcome

Substances

Mercaptopurine
Protein Tyrosine Phosphatase, Non-Receptor Type 11